John Suh, MD

Appointed
1991

Education & Fellowships

Fellowship - Cleveland Clinic
Radiation Oncology
Cleveland, OH
1995

Residency - Cleveland Clinic
Radiation Oncology
Cleveland, OH
1994

Internship - Cleveland Clinic
Transitional
Cleveland, OH
1991

Medical Education - University of Miami School of Medicine
MD
Miami, FL
1990

Undergraduate - University of Miami
Biology
Coral Gables, FL
1986

Professional Highlights

• Chairman of the Department of Radiation Oncology
• Associate Director of Cleveland Clinic's Gamma Knife Radiosurgery Center
• Former Residency Program Director for Department of Radiation Oncology

Certifications

• Radiology - Radiation Oncology

Specialty Interests

Brain tumor, gamma knife

Awards & Honors

•  America’s Top Doctors for Cancer 2009-2013 (Castle Connolly)

  National Brain Tumor Foundation Clinical Research Award, presented at Society of Neuro-Oncology meeting, 2003
• ESTRO/ASTRO Traveling Fellowship Award, 1999

Memberships

• International Stereotactic Radiosurgery Society (ISRS)
• American College of Radiology (ACR)
• American Society of Therapeutic Radiology and Oncology (ASTRO)
• Society of Chairmen of Academic Radiation Oncology Programs (SCAROP) 
• Society of Neuro-Oncology (SNO)

See publications for John Suh, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/14/2024, Dr. Suh has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Royalty Payments. Dr. Suh receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

• MedLever, Inc.

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Suh may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• MedLever, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.